FK506 and erectile function preservation in the cavernous nerve injury model: optimal dosing and timing

Mulhall, J P; Müller, A; Donohue, J F; Golijanin, D; Tal, R; Akin-Olugbade, Y; Kobylarz, K; Cohen-Gould, L; Bennett, N E; Scardino, P

doi:10.1111/j.1743-6109.2008.00776.x

Citations

Citation copied

Mulhall, J. P., Müller, A., Donohue, J. F., Golijanin, D., Tal, R., Akin-Olugbade, Y., Kobylarz, K., Cohen-Gould, L., Bennett, N. E., & Scardino, P. (2008). FK506 and erectile function preservation in the cavernous nerve injury model: optimal dosing and timing. Journal of Sexual Medicine, 5(6), 1334–1344. https://doi.org/10.1111/j.1743-6109.2008.00776.x

Abstract

INTRODUCTION: The immunophilin-ligand FK506 has been shown to ameliorate erectile function and preserve cavernous nerve (CN) architecture in short-term-studies using rat models of CN injury. AIM: The aim of this series was to ascertain the optimal dose and timing of FK506 administration in this animal model. METHODS: Rats underwent bilateral CN crush and were treated with FK506 at different time points. There were control (C) and sham groups for each time point. Based on preliminary experiments, the CN-crush rats had no treatment (C)